---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071357"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:01:09.825376+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics Q1 net loss $32.8M; cash $294.4M; MZE829/MZE782 milestones reiterated

## Summary
- Cash and cash equivalents: $294.4M at March 31, 2025, up from $196.8M at Dec 31, 2024; runway into H2 2027.
- Net loss of $32.8M for Q1 2025, vs $32.5M in Q1 2024; R&D expenses $27.6M (up from $21.9M).
- MZE829 Phase 2 HORIZON trial enrolling APOL1 kidney disease patients; initial proof-of-concept data expected Q1 2026.
- MZE782 Phase 1 healthy volunteer trial ongoing; initial biomarker data expected Q3 2025.
- Cash increase largely from IPO proceeds; no revenue reported (clinical-stage biotech).

## SEC filing metadata
- accession: 0000950170-25-071357
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/0000950170-25-071357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/maze-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071357
- JSON: https://secwatch.observer/filing/0000950170-25-071357.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.